Patents by Inventor Charles D. Leahy
Charles D. Leahy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10010502Abstract: A non-degradable topical ocular drug delivery device includes about 0.001% to about 10% w/w of at least one myopia-suppressing agent complexed with an immobile acid within a crosslinked polymer matrix. The cross-linked polymer matrix is configured to deliver the least one myopia-suppressing agent over an extended period of time at a concentration and rate that controls myopia progression while preserving pupillary function and accommodation.Type: GrantFiled: May 19, 2016Date of Patent: July 3, 2018Assignee: AMORPHEX THERAPEUTICS LLCInventors: Charles D. Leahy, Edward J. Ellis
-
Publication number: 20160338947Abstract: A non-degradable topical ocular drug delivery device includes about 0.001% to about 10% w/w of at least one myopia-suppressing agent complexed with an immobile acid within a crosslinked polymer matrix. The cross-linked polymer matrix is configured to deliver the least one myopia-suppressing agent over an extended period of time at a concentration and rate that controls myopia progression while preserving pupillary function and accommodation.Type: ApplicationFiled: May 19, 2016Publication date: November 24, 2016Inventors: Charles D. Leahy, Edward J. Ellis
-
Patent number: 8679078Abstract: An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery device and contains an active pharmaceutical agent, a lubricant, etc.Type: GrantFiled: September 17, 2012Date of Patent: March 25, 2014Assignee: Vista Scientific LLCInventors: Charles D. Leahy, Denis Labombard
-
Publication number: 20130023838Abstract: An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery device and contains an active pharmaceutical agent, a lubricant, etc.Type: ApplicationFiled: September 17, 2012Publication date: January 24, 2013Applicant: VISTA SCIENTIFIC LLCInventors: Charles D. Leahy, Denis Labombard
-
Patent number: 8287504Abstract: An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery device and contains an active pharmaceutical agent, a lubricant, etc.Type: GrantFiled: July 22, 2010Date of Patent: October 16, 2012Assignee: Vista Scientific LLCInventors: Charles D. Leahy, Denis Labombard
-
Publication number: 20120109054Abstract: A device is disclosed for delivering an active agent to target tissue at a site that includes a bodily fluid. The device includes a body that has an erodible member that releases the active agent over a prescribed period of time.Type: ApplicationFiled: October 29, 2011Publication date: May 3, 2012Applicant: VISTA SCIENTIFIC LLCInventors: Robert F. Thompson, Charles D. Leahy, Edward J. Ellis
-
Patent number: 8167855Abstract: An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery device and contains an active pharmaceutical agent, a lubricant, etc.Type: GrantFiled: August 25, 2004Date of Patent: May 1, 2012Assignee: Vista Scientific LLCInventors: Charles D. Leahy, Denis Labombard
-
Publication number: 20100331796Abstract: An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery device and contains an active pharmaceutical agent, a lubricant, etc.Type: ApplicationFiled: July 22, 2010Publication date: December 30, 2010Applicant: VISTA SCIENTIFIC LLCInventors: Charles D. Leahy, Denis Labombard
-
Publication number: 20040220089Abstract: The present invention relates to an aqueous formulation to be instilled into the eye, or in which to pre soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac. The preparations disclosed are utilized for the treatment of a tear film and ocular surface disorder known as keratoconjunctivitis sicca or dry eye syndrome. In general, the preparations of this invention are also effective for the relief of symptoms of eye irritation, such as those caused by dry environmental conditions or by contact lens wear. In accordance with the present invention, the ophthalmic preparation includes a glycoprotein component, similar to that found at the normal human ocular surface and in one exemplary and preferred embodiment, the glycoproteins are derived from mammalian milk, preferably bovine.Type: ApplicationFiled: March 30, 2004Publication date: November 4, 2004Inventors: Edward J. Ellis, Charles D. Leahy, Jeanne Y. Ellis
-
Publication number: 20040214754Abstract: The present invention relates to an aqueous formulation to be instilled into the eye, or in which to pre soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac. The preparations disclosed are utilized for the treatment of a tear film and ocular surface disorder known as keratoconjunctivitis sicca or dry eye syndrome. In general, the preparations of this invention are also effective for the relief of symptoms of eye irritation, such as those caused by dry environmental conditions or by contact lens wear. In accordance with the present invention, the ophthalmic preparation includes a glycomacropeptide component, similar to that found at the normal human ocular surface and in one exemplary and preferred embodiment, the glycomacropeptide is derived from mammalian milk, preferably bovine.Type: ApplicationFiled: March 30, 2004Publication date: October 28, 2004Inventors: Edward J. Ellis, Charles D. Leahy, Jeanne Y. Ellis
-
Patent number: 6429194Abstract: Aqueous ophthalmic preparations are provided and are intended to be instilled into the eye, or in which to pre soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac. The preparations disclosed are utilized for the treatment of a tear film and ocular surface disorder known as keratoconjunctivitis sicca or dry eye syndrome. In general, the preparations of this invention are also effective for the relief of symptoms of eye irritation, such as those caused by dry environmental conditions or by contact lens wear. In accordance with the present invention, the ophthalmic preparation includes a mucin component, similar to that found at the normal human ocular surface and in one exemplary and preferred embodiment, the mucin is a transmembrane or surface mucin.Type: GrantFiled: June 22, 2001Date of Patent: August 6, 2002Assignee: Vista Scientific LLCInventors: Charles D. Leahy, Edward J. Ellis, Jeanne Y. Ellis
-
Publication number: 20020037842Abstract: Aqueous ophthalmic preparations are provided and are intended to be instilled into the eye, or in which to pre soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac. The preparations disclosed are utilized for the treatment of a tear film and ocular surface disorder known as keratoconjunctivitis sicca or dry eye syndrome. In general, the preparations of this invention are also effective for the relief of symptoms of eye irritation, such as those caused by dry environmental conditions or by contact lens wear. In accordance with the present invention, the ophthalmic preparation includes a mucin component, similar to that found at the normal human ocular surface and in one exemplary and preferred embodiment, the mucin is a transmembrane or surface mucin.Type: ApplicationFiled: June 22, 2001Publication date: March 28, 2002Inventors: Charles D. Leahy, Edward J. Ellis, Jeanne Y. Ellis
-
Patent number: 6281192Abstract: The present invention discloses the ophthalmic applications of mucin derived from mammalian milk or milk byproducts. This mucin has been found to be a MUC1 type mucin similar to the transmembrane mucin expressed on the surface of the human eye. The mucin-containing preparations described in this invention can be in the form of an aqueous formulation to be instilled into the eye, or in which to pre-soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac. The preparations disclosed are utilized for the treatment of tear film and ocular surface disorders associated with the signs and symptoms of dry eye. Furthermore, mucin-based formulations are also effective for the relief of symptoms of eye irritation, such as those caused by environmental conditions or by contact lens wear.Type: GrantFiled: March 1, 2000Date of Patent: August 28, 2001Assignee: Vista Scientific LLCInventors: Charles D. Leahy, Edward J. Ellis, Jeanne Y. Ellis